JP2010513300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513300A5 JP2010513300A5 JP2009541572A JP2009541572A JP2010513300A5 JP 2010513300 A5 JP2010513300 A5 JP 2010513300A5 JP 2009541572 A JP2009541572 A JP 2009541572A JP 2009541572 A JP2009541572 A JP 2009541572A JP 2010513300 A5 JP2010513300 A5 JP 2010513300A5
- Authority
- JP
- Japan
- Prior art keywords
- obese patients
- bmi
- pharmaceutically acceptable
- use according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 239000002461 renin inhibitor Substances 0.000 claims description 8
- 229940086526 renin-inhibitors Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002934 diuretic Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 2
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87018006P | 2006-12-15 | 2006-12-15 | |
| PCT/US2007/087322 WO2008074001A1 (en) | 2006-12-15 | 2007-12-13 | Renin inhibitors for the prevention and treatment of hypertension in obese patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513300A JP2010513300A (ja) | 2010-04-30 |
| JP2010513300A5 true JP2010513300A5 (https=) | 2011-02-03 |
Family
ID=39186152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541572A Withdrawn JP2010513300A (ja) | 2006-12-15 | 2007-12-13 | 肥満患者における高血圧の予防および処置のためのレニン阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100029775A1 (https=) |
| EP (1) | EP2094259A1 (https=) |
| JP (1) | JP2010513300A (https=) |
| KR (1) | KR20090090384A (https=) |
| CN (1) | CN101583355A (https=) |
| AU (1) | AU2007333095B2 (https=) |
| BR (1) | BRPI0721167A2 (https=) |
| CA (1) | CA2672579A1 (https=) |
| CL (1) | CL2007003628A1 (https=) |
| IL (1) | IL198876A0 (https=) |
| MA (1) | MA31003B1 (https=) |
| MX (1) | MX2009006340A (https=) |
| NO (1) | NO20092597L (https=) |
| RU (1) | RU2009126741A (https=) |
| TN (1) | TN2009000240A1 (https=) |
| TW (1) | TW200831071A (https=) |
| WO (1) | WO2008074001A1 (https=) |
| ZA (1) | ZA200903442B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2143425A1 (de) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| AR047880A1 (es) * | 2004-02-17 | 2006-03-01 | Novartis Ag | COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS |
| NZ549535A (en) * | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| WO2007047351A2 (en) * | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
| US20070293552A1 (en) * | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
-
2007
- 2007-12-13 KR KR1020097014655A patent/KR20090090384A/ko not_active Withdrawn
- 2007-12-13 AU AU2007333095A patent/AU2007333095B2/en not_active Ceased
- 2007-12-13 WO PCT/US2007/087322 patent/WO2008074001A1/en not_active Ceased
- 2007-12-13 MX MX2009006340A patent/MX2009006340A/es not_active Application Discontinuation
- 2007-12-13 BR BRPI0721167-8A patent/BRPI0721167A2/pt not_active IP Right Cessation
- 2007-12-13 JP JP2009541572A patent/JP2010513300A/ja not_active Withdrawn
- 2007-12-13 US US12/519,189 patent/US20100029775A1/en not_active Abandoned
- 2007-12-13 EP EP07865611A patent/EP2094259A1/en not_active Withdrawn
- 2007-12-13 RU RU2009126741/15A patent/RU2009126741A/ru not_active Application Discontinuation
- 2007-12-13 CA CA002672579A patent/CA2672579A1/en not_active Abandoned
- 2007-12-13 CN CNA2007800499179A patent/CN101583355A/zh active Pending
- 2007-12-14 CL CL200703628A patent/CL2007003628A1/es unknown
- 2007-12-14 TW TW096148110A patent/TW200831071A/zh unknown
-
2009
- 2009-05-19 ZA ZA200903442A patent/ZA200903442B/xx unknown
- 2009-05-21 IL IL198876A patent/IL198876A0/en unknown
- 2009-06-12 TN TNP2009000240A patent/TN2009000240A1/fr unknown
- 2009-06-17 MA MA32007A patent/MA31003B1/fr unknown
- 2009-07-08 NO NO20092597A patent/NO20092597L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Atlas | The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition | |
| ME00479B (me) | Lijek za profilaksu i tretman arterioskleroze i hipertenzije | |
| KR20050008717A (ko) | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는약제학적 조성물 | |
| EP3027183B1 (en) | Selective at2 receptor agonists for use in treatment of cachexia | |
| WO2000066104A9 (en) | Ace-2 inhibiting compounds and methods of use thereof | |
| JP2012046531A (ja) | 医薬組合せ剤 | |
| WO2001060370A1 (en) | Remedies for endothelin-induced diseases | |
| JP2010513300A5 (https=) | ||
| TWI701043B (zh) | 包含血管收縮素-II受體阻斷劑及ＨＭＧ-ＣｏＡ還原酶抑制劑之醫藥組合製劑及其製備方法 | |
| Meredith | Candesartan cilexetil–a review of effects on cardiovascular complications in hypertension and chronic heart failure | |
| ES2213296T3 (es) | Uso de un antagonista del receptor de angiotensina ii para la preparacion de medicamentos para aumentar la tasa de supervivencia de pacientes con trasplante renal. | |
| Van Zwieten | Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences | |
| Dodson | Hypertension and diabetes | |
| JPWO2011162390A1 (ja) | 徐放性高血圧および腎機能障害治療剤 | |
| TW201000097A (en) | Medicament for the prophylaxis or treament of hypertension | |
| IL276474B2 (en) | Modified bisphenyl butanoic ester derivatives as nep inhibitors | |
| US20120088730A1 (en) | Use of angiotensin converting enzyme (ace) domain specific inhibitors to inhibit or enhance cytokine production and alter immune response | |
| WO2003007964A1 (en) | Remedial or preventive agent for cardiopathy or aneurysm containing chymase inhibitory compound | |
| CN110215455A (zh) | 一种用于降血压的药物配方 | |
| Chaabouni et al. | ALDOSTERONE IN POLYCYSTIC OVARY SYNDROME | |
| Galceran et al. | Renin Angiotensin System and Obesity-Related Organ Damage | |
| Saez et al. | The renin inhibitor aliskiren as novel treatment for cardiovascular disease | |
| Mirkabilovich et al. | The effectiveness of ACE inhibitors and sartans patients with acute myocardial infarction in the elderly on a distant stage monitoring | |
| JP2012254975A (ja) | Ａｃｅ阻害剤とｌ−アルギニンを含有する医薬組成物 | |
| Montereggi et al. | PREVALENCE AND PATTERNS OF HYPERTENSION IN OBESE BARIATRIC PATIENTS: PP. 34.433 |